Wednesday, November 30, 2016

BRIEF-H Lundbeck: FDA accepts sNDA for the expanded labeling of Abilify Maintena

* U.S. FDA accepts for review a supplemental new drug

application to expand labeling of Abilify Maintena

(Aripiprazole) for the treatment of Bipolar I disorder

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)